Fig. 2: Progression-free survival and overall survival in patients with extranodal relapsed/refractory large B-cell lymphoma undergoing CAR-T.

A PFS probability by year from the start of CAR-T. B OS probability by year from the start of CAR-T.

A PFS probability by year from the start of CAR-T. B OS probability by year from the start of CAR-T.